Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.

Item

http://www.wikidata.org/entity/Q37810305

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical experience of QuantiFERON

@nl

Clinical experience of QuantiF ...... sis factor blockers in Taiwan.

@en

type

Item

label

Clinical experience of QuantiFERON

@nl

Clinical experience of QuantiF ...... sis factor blockers in Taiwan.

@en

prefLabel

Clinical experience of QuantiFERON

@nl

Clinical experience of QuantiF ...... sis factor blockers in Taiwan.

@en

P1476

Clinical experience of QuantiF ...... sis factor blockers in Taiwan.

@en

P2093

H-Y Chiu

http://www.w3.org/2001/XMLSchema#string

P-R Hsueh

http://www.w3.org/2001/XMLSchema#string

T-F Tsai

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study.

Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis.

P304

553-559

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2133.2010.10137.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

164

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21083541

http://www.w3.org/2001/XMLSchema#string

P921

TNF